EGCG has been shown in preclinical studies to demonstrate anti-cancer activity through a variety of mechanisms, including decreases in IGF1, tumor-associated oxidative stress and angiogenesis, and androgen receptor antagonism (168–170). Here, IGF1 is linked to neoplasm.